# Syncromune

Source: https://onco.cc/companies/syncromune/  
OnCo record `syncromune` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Syncromune's treatment, SYNC-T, freezes and breaks down a small part of one tumour and then infuses a mix of immune-stimulating drugs directly into it, aiming to train the immune system to attack cancer throughout the body. It is in a phase 2 trial for advanced prostate cancer that no longer responds to hormone treatment.

## Summary

Syncromune, Inc., at 2919 East Commercial Boulevard, Fort Lauderdale, Florida, develops the SYNC-T solid tumour immunotherapy platform, a personalised in situ approach that combines partial cryolysis of a small part of a tumour with infusion of a multi-target biologic drug directly into the tumour, designed to address several immune suppression mechanisms at once while stimulating an immune response. Its leadership includes Charles Link, who previously founded NewLink Genetics. The first candidate, SYNC-T Therapy SV-102, is being evaluated in LEGION-100, a phase 2 trial in metastatic castration-resistant prostate cancer, following a phase 1 study for which the company reported long-term data in October 2026 and presented updated overall survival at ESMO 2026. Its first registered cancer trial, NCT06533644 (LEGION-100), was posted on ClinicalTrials.gov in August 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Syncromune, Inc.
- HQ: Fort Lauderdale, FL
- Type: biotech
- Website: https://syncromune.com/

## Notes

- Founding year not stated on the company website.
- The components of the SV-102 multi-target biologic drug are not listed on the pages read, so no targets or drugs are recorded.
- The company's news page links to an Endpoints News report of a USD 100 million Series A in December 2024; the report itself was not read, so no funding row is recorded.
- The company website states that its content is intended for healthcare professionals.
- Company website read on 29 October 2026.

## Sources

- Official website: https://syncromune.com/
- SYNC-T platform and pipeline: https://syncromune.com/science/
- Long-term phase 1 data in metastatic prostate cancer, October 2026: https://syncromune.com/2026/10/27/syncromune-reports-long-term-data-from-phase-1-study-in-metastatic-prostate-cancer-with-investigational-sync-t-therapy-sv-102/
- ClinicalTrials.gov: LEGION-100 phase 2 trial of SV-102 (NCT06533644): https://clinicaltrials.gov/study/NCT06533644

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Cryoablation systems](https://onco.cc/technologies/cryoablation-systems/), [In situ vaccination](https://onco.cc/technologies/in-situ-vaccination/)
- trials: [A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct06533644/)

---
JSON: https://onco.cc/api/v1/entities/syncromune.json